Hepcidin

What is Hepcidin?

Hepcidin is a 25-amino-acid cysteine-rich peptide hormone (four disulfide bonds, ~2.8 kDa) produced predominantly by hepatocytes and secreted into circulation, with the liver as its dominant source. It was independently discovered at the turn of the 2000s as an antimicrobial peptide (LEAP-1 by Krause et al., 2000; hepcidin by Park et al., 2001), and re-contextualized almost immediately as the long-sought iron-regulatory hormone when Nicolas and colleagues (2001–2002) showed that hepcidin-deficient mice developed progressive iron overload and hepcidin-overexpressing mice developed severe iron-deficiency anemia. Hepcidin's mechanism of action was defined in 2004 when Nemeth and colleagues (Ganz/Kaplan laboratories) demonstrated that hepcidin binds to ferroportin — the only known cellular iron exporter — triggering its internalization and lysosomal degradation. The net effect: high hepcidin sequesters iron inside enterocytes and macrophages and suppresses serum iron; low hepcidin permits iron egress into plasma. Hepcidin is not currently an approved therapeutic, but the hepcidin mimetic rusfertide (PTG-300; Protagonist Therapeutics/Takeda) is in late-stage clinical development for polycythemia vera, where endogenous hepcidin is inappropriately suppressed and red blood cell mass is chronically elevated.

What Hepcidin Is Investigated For

Hepcidin is studied primarily as a physiological hormone, a diagnostic biomarker, and a drug target — not as a self-administered wellness peptide. The strongest evidence surrounds its role in iron homeostasis: hepcidin excess (driven by IL-6 in inflammation) causes the hypoferremia and anemia of chronic disease seen in CKD, cancer, rheumatoid arthritis, and chronic infection; hepcidin deficiency (from HFE, HJV, HAMP, or TFR2 mutations) causes hereditary hemochromatosis. The emerging therapeutic story is the hepcidin-mimetic rusfertide (PTG-300) for polycythemia vera, which met its primary endpoint in the phase 2 REVIVE trial (NEJM 2024) and the phase 3 VERIFY trial, supporting an NDA submission. Hepcidin antagonists for anemia of inflammation are earlier-stage. Hepcidin also has genuine in vitro antimicrobial activity — it was originally isolated from urine for that reason — but its practical clinical significance is as the master iron-regulatory hormone, not as an antibiotic. Synthetic hepcidin sold for self-injection through research-chemical channels has no clinical evidence base, and manipulating systemic iron availability in an untested way carries real risk (iatrogenic iron-restricted anemia, worsened anemia of inflammation, or unintended iron sequestration).

History & Discovery

Hepcidin's discovery is a case study in how a peptide's biological identity can be completely rewritten within a few years of its isolation. In 2000, Axel Krause and colleagues at IPF PharmaCeuticals in Hannover screened human blood ultrafiltrate for novel cysteine-rich antimicrobial peptides using a mass-spectrometric approach, and reported in FEBS Letters the identification of LEAP-1 (liver-expressed antimicrobial peptide 1) — a 25-amino-acid peptide with four disulfide bonds, expressed predominantly in the liver and possessing modest antibacterial activity. The following year, Chan Park, Erika Valore, Alan Waring, and Tomas Ganz at UCLA independently isolated the same peptide from human urine, noted its hepatic origin and antimicrobial activity, and named it hepcidin ('hep' for hepatic, 'cidin' for cidal). Both groups characterized it as an antimicrobial peptide. The iron story emerged almost immediately afterward, and from an unexpected direction. Sophie Vaulont's group at the Institut Cochin in Paris had generated a knockout of upstream stimulatory factor 2 (USF2), expecting a transcriptional phenotype. The mice instead developed severe, progressive iron overload. Differential expression analysis revealed that the knockouts had completely lost expression of a neighboring gene on the same genomic locus — hepcidin. Gaël Nicolas and colleagues reported this finding in PNAS in 2001, making the provocative case that hepcidin, just identified as an antimicrobial peptide, was in fact the long-sought iron-regulatory hormone. The same group confirmed the inverse phenotype the following year: transgenic mice overexpressing hepcidin in the liver developed severe iron-deficiency anemia at birth (Nicolas et al., PNAS 2002). In parallel, Christelle Pigeon and colleagues in Rennes showed in J Biol Chem (2001) that hepcidin was induced in the liver under iron overload. The human genetic validation came rapidly. In 2003, Antonella Roetto, Clara Camaschella, and colleagues in Turin reported in Nature Genetics that two families with severe juvenile hemochromatosis carried mutations in HAMP itself — establishing hepcidin deficiency as a direct cause of human iron-overload disease. Mutations in HJV (hemojuvelin), HFE, and TFR2 were all subsequently shown to converge on inadequate hepcidin induction in response to body iron. The mechanistic keystone was placed in 2004, when Elizabeta Nemeth, Tomas Ganz, and Jerry Kaplan's collaborating laboratories reported in Science that hepcidin binds directly to ferroportin — the only known cellular iron exporter, identified just a few years earlier by Andrew McKie and by Nancy Andrews — and triggers its internalization and lysosomal degradation. That same year, Nemeth and colleagues published in JCI that IL-6 is the necessary and sufficient cytokine for hepcidin induction in inflammation, establishing the cytokine-hepcidin link that underlies anemia of chronic disease. Within four years of its isolation as an antimicrobial peptide, hepcidin had become the organizing concept for systemic iron biology. The decade that followed filled in regulatory detail: the BMP6-SMAD signaling axis as the iron-sensing pathway (Andrews, Rivella, Ganz labs and others), erythroferrone as the erythroid suppressor of hepcidin (Léon Kautz and colleagues, Nature Genetics 2014), and the structural basis of hepcidin-ferroportin binding resolved by cryo-EM in the early 2020s. The drug-development arc has moved in parallel. Hepcidin agonists aim to reproduce hepcidin's iron-restricting effect in conditions of pathologic iron excess or unrestricted erythropoiesis — most prominently rusfertide (PTG-300), a Protagonist Therapeutics peptide mimetic (now partnered with Takeda) that showed efficacy in phlebotomy-dependent polycythemia vera in the phase 2 REVIVE trial (NEJM 2024) and met its primary endpoint in the phase 3 VERIFY trial, supporting NDA submission. Hepcidin antagonists — intended for anemia of chronic disease, CKD anemia, and β-thalassemia — are earlier in development, with multiple mechanisms under investigation (anti-BMP6, anti-hemojuvelin, TMPRSS6-targeting antisense oligonucleotides, direct anti-hepcidin antibodies).

How It Works

Hepcidin is the body's iron thermostat, made by the liver. Think of ferroportin as a door on the cells that store and release iron — enterocytes in the gut (which absorb iron from food) and macrophages (which recycle iron from old red blood cells). Hepcidin's job is to walk up to ferroportin, grab it, and drag it off the cell surface into the trash. When hepcidin is high, the doors close and iron stays stuck inside cells; serum iron drops. When hepcidin is low, the doors stay open and iron flows into the blood. Inflammation cranks hepcidin up (causing the 'iron-locked' anemia of chronic disease). Iron deficiency and active red blood cell production push hepcidin down (opening the doors). Hereditary hemochromatosis is, at its core, a state of inappropriately low hepcidin — the doors never fully close, iron keeps pouring in, and the body slowly poisons itself with iron.

Hepcidin is encoded by the HAMP gene on chromosome 19q13 and is synthesized primarily by hepatocytes as an 84-amino-acid preprohepcidin, processed through prohepcidin to the bioactive 25-amino-acid mature peptide (hepcidin-25), which is released into the circulation. The mature peptide contains eight cysteine residues forming four intramolecular disulfide bonds and an N-terminal region that is essential for biological activity (N-terminally truncated forms, hepcidin-22 and hepcidin-20, have reduced or absent ferroportin-binding function). Hepcidin's canonical mechanism, established by Nemeth et al. (Science 2004), is direct binding to ferroportin (SLC40A1) — the only known cellular iron efflux transporter — at the cell surface. Binding induces ferroportin internalization via ubiquitination of cytoplasmic lysines, followed by lysosomal degradation. The cells most affected are duodenal enterocytes (which export dietary iron into portal circulation), splenic and hepatic macrophages (which recycle iron from senescent erythrocytes and provide roughly 20–25 mg of iron per day for erythropoiesis), and hepatocytes (which store iron as ferritin). With ferroportin degraded, iron is trapped intracellularly: dietary iron absorption falls, macrophage iron recycling stalls, and serum iron and transferrin saturation decline within hours. Hepcidin transcription in hepatocytes is regulated by four major signaling inputs. (1) Iron status: circulating transferrin-bound iron and hepatic iron stores signal through BMP6 (produced by liver sinusoidal endothelial cells) to activate BMP receptors (ALK2/ALK3) and phosphorylate SMAD1/5/8, which, with co-SMAD4, drives HAMP transcription. Hemojuvelin (HJV) is an obligate co-receptor; HFE and TFR2 sense transferrin saturation and feed into the same pathway. (2) Inflammation: IL-6 signals through IL-6R/gp130/JAK2 to activate STAT3, which binds the HAMP promoter — the cytokine-hepcidin link that underlies anemia of chronic disease (Nemeth et al., JCI 2004). (3) Erythropoietic drive: erythroferrone (ERFE), secreted by erythroblasts in response to erythropoietin (Kautz et al., Nature Genetics 2014), suppresses hepcidin by sequestering BMP6 and related ligands — providing iron for accelerated erythropoiesis. (4) Hypoxia: HIF-mediated and ERFE-mediated pathways both contribute to hepcidin suppression under hypoxic stress. Disordered hepcidin is the proximate cause of multiple iron disorders. Loss-of-function mutations in HFE, HJV, HAMP, and TFR2 cause hereditary hemochromatosis via inadequate hepcidin response to iron loading. Gain-of-function-like states occur in TMPRSS6 deficiency (iron-refractory iron-deficiency anemia, IRIDA) and in the chronic IL-6 elevation of inflammation, malignancy, and CKD — producing anemia of chronic disease. In polycythemia vera, endogenous hepcidin is inappropriately suppressed by erythroferrone-driven erythropoietic signaling, sustaining the expanded red cell mass; rusfertide reverses this pharmacologically.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Hepcidin:

• 01Whether hepcidin antagonists (anti-BMP6, anti-HJV, TMPRSS6 ASOs, anti-hepcidin antibodies) produce durable hemoglobin improvement in anemia of chronic disease without clinically meaningful infection or iron-overload signals remains to be established in adequate trials.
• 02Long-term (multi-year) safety and efficacy of rusfertide and related hepcidin agonists in polycythemia vera — particularly impact on thrombotic events, symptom burden, and disease progression beyond hematocrit control — requires post-approval real-world evidence.
• 03Diagnostic use of serum hepcidin assays for differentiating iron deficiency anemia from anemia of chronic disease, and for guiding ESA/iron therapy in CKD, is mechanistically sound but under-standardized across laboratories and not yet part of routine US clinical practice.
• 04The role of hepcidin in obesity-associated anemia and in iron-biomarker derangements of the metabolic syndrome is biologically plausible (chronic low-grade inflammation drives hepcidin) but clinically underexplored.
• 05Whether correcting TMPRSS6 in iron-refractory iron-deficiency anemia (IRIDA) via antisense or small-molecule approaches can restore effective iron absorption in these patients is an active area of early-phase development.
• 06Interactions between hepcidin, erythroferrone, and the HIF-PHD axis under treatment with oral HIF-PHD inhibitors (roxadustat, daprodustat, vadadustat) — which modulate both endogenous EPO and, indirectly, hepcidin — are still being characterized in longitudinal pharmacovigilance.

Forms & Administration

Endogenous hepcidin is not administered — it is an intrinsic liver-secreted hormone. Synthetic hepcidin-25 exists as a research reagent and in early pharmacology studies, but the clinically relevant molecule is the investigational hepcidin mimetic rusfertide (PTG-300), which is administered by subcutaneous injection weekly in phase 2/3 trials for polycythemia vera. Rusfertide is not commercially available; it is accessible only within sponsored clinical trials or expanded-access programs. Synthetic hepcidin sold through research-chemical channels is not equivalent to clinical-trial material and is not authorized for human use.

Common Questions

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions